Literature DB >> 17616684

Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.

Han C Dan1, Mazhar Adli, Albert S Baldwin.   

Abstract

The mammalian target of rapamycin (mTOR) is a mediator of cell growth, survival, and energy metabolism at least partly through its ability to regulate mRNA translation. mTOR is activated downstream of growth factors, insulin, and Akt-dependent signaling associated with oncoprotein expression or loss of the tumor-suppressor PTEN. In this regard, mTOR activity is associated with cancer cell growth and survival. Here, we have explored an involvement of the I kappa B kinase (IKK) pathway, associated with nuclear factor-kappaB activation, in controlling mTOR activity. The experiments show that IKK alpha controls mTOR kinase activity in Akt-active, PTEN-null prostate cancer cells, with less involvement by IKK beta. In these cells, IKK alpha associates with mTOR, as part of the TORC1 complex, in an Akt-dependent manner. Additionally, IKKalpha is required for efficient induction of mTOR activity downstream of constitutively active Akt expression. The results indicate a novel role for IKK alpha in controlling mTOR function in cancer cells with constitutive Akt activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616684     DOI: 10.1158/0008-5472.CAN-07-1232

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Authors:  Yu Gao; Ronald B Gartenhaus; Rena G Lapidus; Arif Hussain; Yanting Zhang; Xinghuan Wang; Han C Dan
Journal:  Mol Cancer Res       Date:  2015-09-15       Impact factor: 5.852

Review 2.  NF-kappaB in carcinoma therapy and prevention.

Authors:  Matthew Brown; Jonah Cohen; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Expert Opin Ther Targets       Date:  2008-09       Impact factor: 6.902

3.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Future Neurol       Date:  2012-11

4.  p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation.

Authors:  William C Comb; Jessica E Hutti; Patricia Cogswell; Lewis C Cantley; Albert S Baldwin
Journal:  Mol Cell       Date:  2012-02-16       Impact factor: 17.970

5.  NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo.

Authors:  Ashley Wysong; Marion Couch; Scott Shadfar; Luge Li; Lugi Li; Jessica E Rodriguez; Scott Asher; Xiaoying Yin; Mitchell Gore; Al Baldwin; Cam Patterson; Monte S Willis
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

6.  TSC1 controls IL-1β expression in macrophages via mTORC1-dependent C/EBPβ pathway.

Authors:  Tao Yang; Linnan Zhu; Yanhua Zhai; Qingjie Zhao; Jianxia Peng; Hongbing Zhang; Zhongzhou Yang; Lianfeng Zhang; Wenjun Ding; Yong Zhao
Journal:  Cell Mol Immunol       Date:  2015-05-25       Impact factor: 11.530

7.  S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.

Authors:  Jin Zhang; Zhanguo Gao; Jun Yin; Michael J Quon; Jianping Ye
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

8.  Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).

Authors:  Han C Dan; Aaron Ebbs; Manolis Pasparakis; Terry Van Dyke; Daniela S Basseres; Albert S Baldwin
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

9.  The receptor interacting protein 1 mediates a link between NFkappaB and PI3-kinase signaling.

Authors:  Sandili S Chauncey; David A Boothman; Amyn A Habib
Journal:  Cell Cycle       Date:  2009-09-23       Impact factor: 4.534

Review 10.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.